Beta Adrenergic Signaling as a Therapeutic Target for Autoimmunity.

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Beta-adrenergic receptors (β1/2) play a role in T _H 17 lymphocyte development.
• Combined inhibition of β1/2 receptors impairs IL-17A production and promotes T _reg cells.
• The therapeutic potential for autoimmune disorders mediated by IL-17A remains unclear.

Purpose of the Study:

• To investigate the impact of β1/2 adrenergic receptor blockade on experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis.
• To assess the effect on disease progression, severity, and the balance between T _H 17 and T _reg cells.

Main Methods:

• Utilized genetic deletion and pharmacological blockade of β1/2 adrenergic receptors in a mouse model of EAE.
• Administered propranolol (lipophilic) and nadolol (aqueous) to block β1/2 receptors.
• Initiated treatment at the onset of disease symptoms.

Main Results:

• Genetic and pharmacological blockade of β1/2 receptors significantly reduced EAE severity and weight loss.
• Both systemic and T-lymphocyte-specific genetic deletion of β1/2 receptors attenuated disease.
• Pharmacological blockade shifted the T _H 17/T _reg balance, decreased IL-17A production, and mimicked genetic findings.

Conclusions:

• β1/2 adrenergic signaling critically controls T _H 17/T _reg cell balance in EAE.
• These findings offer new insights into EAE pathogenesis.
• β1/2 receptor blockade presents a potential therapeutic strategy for IL-17A-driven autoimmune diseases.